@Snozz - "Pot stocks down at the moment?"It might have a bit to...

@Snozz - "Pot stocks down at the moment?"

It might have a bit to do with the Australian Rheumatology Assoc. (ARA) coming out with a statement saying it does not recommend the routine use of cannabinoids to treat arthritis and other musculoskeletal conditions. The article is in Cannabiz.
ARA want evidence but there's no mention of Zelira's pain trial with Levin Health which will provide data on pain management.

With such restrictive opinions from professional bodies such as the ARA, Zelira are as well off operating out of the American market, imo.

ZLD were planning to launch a product this year related to Aged Disorder, which I can only think of being arthritis-related, to the American market. Just as well they weren't planning to launch it here because they wouldn't be able to anyway.

Dyor and welcome to the discussion
AE